[Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Human growth hormone (hGH) is an essential therapeutic drug for the treatment of growth hormone (GH) deficiency (GHD).

Who Took Part

The study group was 31 children.

By PubMed's age tags, the people studied were children, both men and women.

A 12-month randomized, open-label, multicenter trial was conducted in 31 previously untreated children with growth failure secondary to GH deficiency [20 boys and 11 girls, mean age (10.5 +/- 4.1) years].

The patients were followed up at 3, 6, 9, and 12 months of the treatment, and the course of treatment was 12 months.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.

More than one site took part, so the children came from several places.

Serum Insulin-like growth factor I (IGF-1), Insulin-like growth factor binding protein 3 (IGFBP-3), GH antibodies and safety parameters were assessed at the baseline and at 3-month intervals.

Bone age (BA) was assessed at the baseline and the rate of skeletal maturation (DeltaBA/DeltaCA) was calculated after 6 and 12 months of rhGH treatment by a central bone age reader.

Moreover, the safety of rhGH solution treatment was assessed.

What Was Measured

PubMed files the paper under topics including China, Dwarfism, Pituitary, Growth Disorders, Human Growth Hormone, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 31 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 14 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (Zhonghua er ke za zhi = Chinese journal of pediatrics), a journal based in China.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.